The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
about
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsIncretin physiology and pathophysiology from an Asian perspectivePharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryThe diabetes susceptibility gene Clec16a regulates mitophagyA Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa JapanPharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Differential proteomic analysis of the pancreas of diabetic db/db mice reveals the proteins involved in the development of complications of diabetes mellitus.Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.Personalized medicine in diabetes mellitus: current opportunities and future prospectsShould Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?Contribution of ENPP1, TCF7L2, and FTO polymorphisms to type 2 diabetes in mixed ancestry ethnic population of South AfricaMarkers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight.Pharmacogenetics of oral antidiabetic drugs.Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Genetics of drug response in type 2 diabetes.Using Personalized Medicine in the Management of Diabetes Mellitus.The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the Netherlands.Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.Functional and association analysis of an Amerindian-derived population-specific p.(Thr280Met) variant in RBPJL, a component of the PTF1 complex.Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study.Inherited pancreatic cancer.Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.Precision medicine in diabetes prevention, classification and management.A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.
P2860
Q26751138-A9FDF7E8-E1A5-4785-8F58-9C5283E68C65Q26784623-D3741E37-C206-4827-AE40-99A84F8053A1Q28274686-15FE7EF8-600A-496A-9616-F41944E7A22BQ28511990-9CDCC251-DBFC-4B82-BDB8-552A513B47C1Q28551748-2A221C23-70E0-476D-A38D-831BE7C37204Q30248914-33A1660B-C1C7-4C88-8A34-CD6E0CF5BAF8Q33907542-6D9EC953-A2E3-4924-BA90-968F0388EEE7Q34314018-E23B22FE-C16B-49BF-B747-CF233342ECBEQ35779453-AE36876A-6D96-49EE-89FA-8873ACABA1A5Q35981408-D52B9B50-8BB0-4345-AC9C-3087FCDF16B8Q36612542-B46D4183-E290-4247-A35E-439908A360E4Q36972891-A565AEA2-3D27-4301-82F6-CFC60335AF98Q37110625-5AA5F462-8152-4389-8896-E3C0EF2097A4Q37353476-A7DDEFD3-5E2A-47E3-98A6-4B704C8B88F5Q37702457-79E06920-5EF6-4B5D-BC2D-FC19934D824EQ38110432-C78176B1-A48F-4051-A3E1-19314000415CQ38480670-42FBF7FB-7AAB-4FB5-85CF-B41068A5819DQ38666166-8F3E1923-8A70-44E2-8F20-2BBA6ADE8088Q38674042-C04EEDBE-C3C0-41D3-9EF8-0CA8370D336EQ38816602-8E598992-A3AB-4F5B-821F-47AED674769BQ38831752-BCA5E37D-109F-46C0-A401-31272C47A129Q40858276-A9E7E96C-73D4-4433-9B12-3CD63BA71B55Q47231163-DFD2689F-96CC-4BD3-B174-445547CD3E97Q47238942-23775113-1A42-413C-BDF2-64E2BE1B8763Q50146622-872CF365-C0E5-4715-A17B-A2A97313077EQ51726149-60B86704-5AF3-492A-9EF2-ED1AEDF85FA9Q52677048-5BF37F15-55D4-4D93-BB16-8A527FBDE656Q53103669-72A2C7A7-3413-49CB-8AFD-B3C6204CC9A0
P2860
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@en
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@nl
type
label
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@en
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@nl
altLabel
The CTRB1/2 ...... tment via the Incretin Pathway
@en
prefLabel
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@en
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@nl
P2093
P2860
P50
P356
P1433
P1476
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
@en
P2093
Andreas Fritsche
Annemarie M C Simonis-Bik
Colin N A Palmer
Eelco J P de Koning
Elisabeth M W Eekhoff
Fausto Machicao
Louise A Donnelly
Marjan Alssema
Mark H H Kramer
Michaela Diamant
P2860
P304
P356
10.2337/DB13-0227
P407
P50
P577
2013-05-14T00:00:00Z